Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $85.2 million.

  • Journey Medical's Liabilities and Shareholders Equity rose 3301.95% to $85.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $331.6 million, marking a year-over-year increase of 2160.22%. This contributed to the annual value of $80.2 million for FY2024, which is 441.39% up from last year.
  • According to the latest figures from Q3 2025, Journey Medical's Liabilities and Shareholders Equity is $85.2 million, which was up 3301.95% from $81.2 million recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Liabilities and Shareholders Equity ranged from a high of $120.9 million in Q1 2022 and a low of $64.0 million during Q3 2024
  • Its 5-year average for Liabilities and Shareholders Equity is $86.5 million, with a median of $85.0 million in 2025.
  • Per our database at Business Quant, Journey Medical's Liabilities and Shareholders Equity surged by 8742.34% in 2021 and then tumbled by 3904.67% in 2023.
  • Journey Medical's Liabilities and Shareholders Equity (Quarter) stood at $97.3 million in 2021, then increased by 8.1% to $105.2 million in 2022, then dropped by 26.92% to $76.8 million in 2023, then increased by 4.41% to $80.2 million in 2024, then increased by 6.17% to $85.2 million in 2025.
  • Its last three reported values are $85.2 million in Q3 2025, $81.2 million for Q2 2025, and $85.0 million during Q1 2025.